American Association for Cancer Research Co-hosts Conference on Molecular Targets and Cancer Therapeutics
September 26, 2013
BOSTON, MASS. — The American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC) will host their annual International Conference on Molecular Targets and Cancer Therapeutics
from Oct. 19-23, 2013, at the Hynes Convention Center in Boston, Mass.
The meeting, focusing on cancer drug development, draws nearly 3,000 attendees and gathers academics, scientists, and representatives from the pharmaceutical industry to discuss the effects new discoveries in cancer therapeutics and target selection have in molecular biology.View the online program
A press kit containing press releases and highlighted abstracts will be available Oct. 14.
Press conferences will take place at 10 a.m. ET, Sunday, Oct. 20, and Monday and Tuesday at 9 a.m. ET. New cancer research highlighted in the International Conference on Molecular Targets and Cancer Therapeutics 2013 press program includes:
- New marker for predicting response in BRAF-mutant melanoma;
- Marker for lung cancer response to sorafenib;
- New diagnostic platform to rapidly detect BRAF mutations;
- The continuing story of PARP inhibitors as they move to phase III trials;
- Potential new agent for treating resistant gastrointestinal stromal tumors;
- Potential new therapies for pancreatic and lung cancers; and
- New therapy for overcoming resistance to antiangiogenic drugs.
Complimentary registration will be available to members of the media who provide press credentials. For more information or to register for the meeting, please contact Lauren Riley at email@example.com
or 215-446-7155 or Jeremy Moore at firstname.lastname@example.org